| Similar Articles |
|---|
 |
BusinessWeek
April 17, 2006
Gene G. Marcial |
A Fresh Prospect For Aspect Some investors are starting to see Aspect Medical Systems, tops in brain monitoring, in a new light.   |
The Motley Fool
July 19, 2005
Stephen D. Simpson |
Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note. |
The Motley Fool
October 14, 2005
Stephen D. Simpson |
Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is. |
The Motley Fool
September 26, 2005
Stephen D. Simpson |
Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors? |
The Motley Fool
May 17, 2006
Stephen D. Simpson |
Angiotech Pharmaceuticals: Rebuilding or Reloading? This small Canadian drug-delivery outfit is reshaping and diversifying. Investors, is it time to buy? |
The Motley Fool
June 22, 2005
Stephen D. Simpson |
Stent Wars: Jury Strikes Back A jury finds that Boston Scientific has violated J&J's stent patents, but the battle is only beginning. Meanwhile, Boston Scientific continues to have market-share leadership in drug-coated stents and makes quite a bit of money from it. |
The Motley Fool
December 5, 2005
Stephen D. Simpson |
Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note. |
The Motley Fool
February 7, 2006
Stephen D. Simpson |
Boston Scientific's Big Task The company won the battle for Guidant, but the hard work hasn't even begun. Value is value, and if Boston Scientific proves it can handle the considerable challenges ahead, this could ultimately be a very interesting stock again. |
The Motley Fool
June 24, 2009
Brian Orelli |
Boston Scientific Helps Itself ... and Its Rivals Boston Scientific released positive results from a clinical trial testing its heart devices, but unfortunately the data is likely to help its competitors as well. |
The Motley Fool
July 23, 2008
Brian Orelli |
Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down. |
The Motley Fool
February 3, 2011
Brian Orelli |
Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes. |
The Motley Fool
April 23, 2008
Brian Orelli |
Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up. |
The Motley Fool
July 23, 2007
Ryan Fuhrmann |
Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note. |
The Motley Fool
February 3, 2011
Thomas Lee |
Boston Scientific Wants to Be a Rock Star. But First, It Needs Some Stars Boston Scientific has been talking the talk of late. But its walk the past few years can be best described as a limp. |
The Motley Fool
July 31, 2006
Stephen D. Simpson |
Can Boston Scientific Get It Right? To boost investor confidence, management must first prove itself. |
CRM
June 10, 2015 |
Fonolo and Aspect Partner to Bring Multichannel Call-Backs to Call Centers Fonolo joins the Aspect Technology Alliance Program. |
The Motley Fool
September 11, 2007
Billy Fisher |
FDA Takes Issue With Boston Scientific Boston Scientific has until later this month to respond to an FDA letter prompted by the company's failure to disclose two of five deaths in a stent trial that the medical device maker abandoned in 2006. Investors take note. |
The Motley Fool
October 13, 2008
Brian Orelli |
Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier. |
The Motley Fool
June 13, 2006
Jim Mueller |
Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note. |
The Motley Fool
January 6, 2009
Brian Orelli |
Boston Scientific Gets Gussied Up Boston Scientific is buying it's current partner, Ireland-based Labcoat. |
The Motley Fool
May 29, 2008
Brian Orelli |
Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific. |
The Motley Fool
January 12, 2007
Billy Fisher |
Big Week at Boston Scientific The company's off to a great start so far for 2007. Investors, take note. |
The Motley Fool
August 12, 2010
Brian Orelli |
Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later. |
The Motley Fool
January 29, 2009
Brian Orelli |
No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed. |
The Motley Fool
February 5, 2008
Brian Orelli |
Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter. |
The Motley Fool
December 31, 2007
Brian Orelli |
Boston Scientific Restarts Its Heart Boston Scientific receives European approval for its defibrillator, giving the company a revenue boost even if the U.S. approval is delayed. |
The Motley Fool
February 1, 2010
Brian Orelli |
Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost. |
BusinessWeek
August 8, 2005
Amy Barrett |
BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals. |
The Motley Fool
October 23, 2008
Brian Orelli |
Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter. |
The Motley Fool
January 17, 2006
Stephen D. Simpson |
High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this. |
BusinessWeek
April 17, 2006
Amy Barrett |
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created. |
The Motley Fool
October 20, 2009
Robert Steyer |
The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it. |
The Motley Fool
July 21, 2010
Brian Orelli |
Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now. |
The Motley Fool
July 29, 2011
Brian Orelli |
Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last? |
The Motley Fool
February 15, 2006
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? Boston Scientific... Franklin Bank... Fossil... Gartner... iPass... |
BusinessWeek
October 9, 2006 |
Boston Scientific's Double Bypass First, quality problems with its defibrillators. Now, doubts about the safety of Boston Scientific's coated stents |
The Motley Fool
September 21, 2010
Brian Orelli |
An Acquisition Helps Boston Scientific Breathe Easier Boston Scientific diversifies by picking up device maker Asthmatx. |
The Motley Fool
June 26, 2009
Brian Orelli |
Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss. |
The Motley Fool
August 14, 2008
Brian Orelli |
Wald Equation Won't Derail Boston Scientific The Wall Street Journal reanalyzes Boston Scientific's data on its new drug-eluding stent, but will the FDA care? |
The Motley Fool
May 28, 2009
Brian Orelli |
Boston Scientific Back in an Atomic Way Can its tiny stent save the day? |
The Motley Fool
April 9, 2010
Brian Orelli |
Is Boston Scientific Turning It Around? Selling off a pair of units could help. |
The Motley Fool
January 11, 2008
Brian Orelli |
Boston Scientific Lives Below Its Means Cost-cutting efforts should help turn the medical-device making company around in 2008. |
The Motley Fool
February 12, 2010
Brian Orelli |
Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year. |
The Motley Fool
December 13, 2006
Matthew Crews |
Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies. |
The Motley Fool
June 29, 2006
Jim Mueller |
Guidant, Devices, and Recalls, Oh My! To repair its acquisition's good name, Boston Scientific must quickly fix Guidant's problems. One analyst sees annual growth for Guidant's devices in the 10% to 15% range. No one knows how accurate that will prove to be, but it certainly provides hope for the troubled acquisition. |
The Motley Fool
May 24, 2006
S.J. Caplan |
Goodbye, Guidant Publicity woes drive Boston Scientific to ditch the Guidant name. In the meantime, Boston Scientific wants to capitalize on its entry into the ICD market, an area experiencing double-digit sales growth. Investors, take note. |
The Motley Fool
May 25, 2010
Brian Orelli |
Medtronic Gets Tossed Out With the Bathwater A bad day to report good news. |
The Motley Fool
April 18, 2006
Stephen D. Simpson |
Get Ready for the New Boston Scientific Here's hoping it does a better job as a bigger business. For all of the risks that are present, there still could be rewards here for investors. |
The Motley Fool
October 18, 2010
Anand Chokkavelu |
There Are Better Opportunities Than Boston Scientific Let's take a look. By the numbers, Abbott, Medtronic, and Johnson & Johnson all look more compelling than Boston Scientific. |
The Motley Fool
March 16, 2010
Brian Orelli |
No Matter What You Call It, It Still Stinks A recall over a paperwork issue? What have you guys been doing? Announcing a recall of your heart defibrillators during a major cardiology meeting probably isn't the best move |
